Think of us as the opensource biotech and research organization with a primary goal of delivering therapeutic strategies and data, holding everyone to account along the way, including ourselves.
25th February: Bina Therapeutics publishes preclinical evaluation study of TRAABA24 which underscores differential mechanisms of action in comparison to standard of care and raised considerations for it’s use.
We’ll be following up with an additional update on how this data will be used to develop TRAABA24 into a therapeutic application for PMP.
30th January: We’ve been refining lab conditions and conducting early tests of TRAABA24 in a lipid nanoparticle formulation across two PMP cell lines. The results highlight its potent activity, achieving a significant impact on cell survival at just one-tenth the dose of Mitomycin C. This reinforces TRAABA24’s therapeutic potential through a distinct mechanism from standard treatments.
7th January: In December 2024, Bina Therapeutics established a master cell bank for Pseudomyxoma Peritonei (PMP) research. As we enter 2025, we’ve successfully cultured PMP cell lines to drive preclinical efforts to validate TRAABA24. Click here for full details and images of the cultured cells.
23rd December: Bina Therapeutics received PMP cell lines from the University of South Carolina to advance in-vitro studies and preclinical validation of TRAABA24. We are deeply grateful to the USC team for their unwavering support and for overcoming festive-period logistical challenges to ensure our progress remained untarnished.
13th Dec: Reply received regarding our purchase order of PMP cell lines (N14a & N15a). Vendor requested further usage information in order to apply the appropriate license type -We responded on the same day.
20th Dec: The vendor responds to our email dated the 13th, outlining “potential terms.” We follow up by requesting definitive terms and a clear turnaround time. Additionally, we inform the vendor that while we have successfully sourced PMP cell lines elsewhere, we remain open to procuring their cell lines, provided their response is timely enough to align with our research requirements.
The team at USC start preparation of PMP cell cultures for dispatch, targeting week commencing 16th December. Subject to logistic efficiency over the Christmas period we aim to secure them before the 23rd December, failing which we’ll aim for taking delivery within December 2024.
In the absence of a response from the “Cell Culture Collections” Vendor, the University of South Carolina graciously agree to provide PMP cell lines enabling the continuation of our planned preclinical work.
An additional chaser email is sent directly to a member of staff at the Innovation Factory, University of Manchester:
“Dear xxxx, In relation to the below, I wondered if you can help. My team are trying to obtain PMP Cell cultures for our research work – we haven’t had any indicative signals or feedback as to when we will be able to place the order and how long it could take to get to us.”
A chaser email is sent to the vendor regarding the cell line order request two weeks ago.
Initial engagement with MHRA to identify best strategy and pathway for registering clinical trials of TRAABA24.
To advance preclinical studies, Bina Therapeutics requires Pseudomyxoma Peritonei cell lines. These scarce resources are sold via the UK Culture Collections website. An online order request was submitted in October 2024, followed by the completion and submission of additional required forms. No reply or next steps are provided by the vendor.
Cell lines requested (links open in a new window):
Archie secures sponsored access to a GMP compliant laboratory to carry out reformulation of TRAABA24 and undertake preclinical studies. These studies aim to validate its activity in PMP cell lines with greater precision, evaluate the efficacy of the formulation strategy, and generate comprehensive data to support regulatory submissions.
Our work and data is shared with Basingstoke colorectal and a collaborative partnership is formed in order to gain input and directional advice on clinical aspects of drug delivery and trial planning.
Ricki and Archie form Bina Therapeutics as a vehicle to develop and deliver an improved therapeutic strategy for patients with rare diseases using Pseudomyxoma Peritonei as a pilot project.
Archie designs a formulation to enhance the delivery and efficacy of the lead compound within the harsh tumor micro environment of Pseudomyxoma Peritonei patients.
An initial positive hit! The compound is tested by a professor of microbiology at the University of South Carolina using PMP cell lines. This preliminary study shows a translational result from in silico to in vitro. The results are shared with PMP researchers and charities across the UK, Europe and USA.
After engaging with PMP and cancer researchers, including the Institute of Cancer Research UK, Ricki presents his findings to a PMP research group led by Professor Thomas McAvoy. A member of the group volunteers to conduct in vitro studies using PMP cell lines based on the data generated from computational analysis.
Ricki connected with NIH-funded scientist and researcher Archie Svetlov to validate his findings. Archie carefully evaluates the compound carrying out independent analysis which confirmed strong drug-like binding to critical targets associated with PMP progression. Providing Ricki with actional data and a strong rationale to pursue these findings further.
Rick Dhal, founder of Bina Therapeutics, develops technology to advance research for novel treatments. After identifying promising small molecules, Ricki uses molecular docking to evaluate their potential, uncovering a strong candidate for repurposing in PMP.
